LCN2 and Cachexia: Furthermore, treatment with the anti-LCN2 antibody alleviated the pathogenic phenotypes of lung cancer cachexia model mice, including the reduction in body weight (Fig. 6H) and eWAT/iWAT wasting (Fig. 6I, J).